Total revenue reached $59.4 million, a 13% increase from $52.4 million in Q1 2025. Domestic revenue grew 11% to $45.3 million, while international revenue surged 22% to $14.1 million. Trauma & Deformity revenue rose 14% to $43.0 million; Scoliosis revenue grew 13% to $15.4 million. Adjusted EBITDA improved to $2.2 million, compared to a loss of $0.4 million in the prior-year period. Free cash flow usage was reduced by 40% year-over-year to $5.0 million. Full-year 2026 revenue guidance increased to a range of $263.0 million to $267.0 million.